The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study.
 
Hironaga Satake
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Koji Ando
No Relationships to Disclose
 
Hisateru Yasui
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Yuji Negoro
No Relationships to Disclose
 
Tatsuya Kinjo
No Relationships to Disclose
 
Koutarou Yuge
No Relationships to Disclose
 
Kenji Baba
No Relationships to Disclose
 
Hiroyuki Orita
No Relationships to Disclose
 
Keiji Hirata
No Relationships to Disclose
 
Mototsugu Shimokawa
No Relationships to Disclose
 
Akitaka Makiyama
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Lilly Japan
 
Hiroshi Saeki
No Relationships to Disclose
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Hideo Baba
Honoraria - Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); AstraZeneca Japan (Inst); bitBiome (Inst); Chugai Pharma (Inst); Eisai (Inst); Johnson & Johnson K.K. (Inst); Lilly Japan (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst)